Interferon Beta-1A + Placebo

Phase 2Terminated

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Preventive Medicine

Conditions

Preventive Medicine, Multi Organ Failure

Trial Timeline

Feb 18, 2017 → Oct 3, 2019

NCT ID

NCT03119701

About Interferon Beta-1A + Placebo

Interferon Beta-1A + Placebo is a phase 2 stage product being developed by Faron Pharmaceuticals for Preventive Medicine. The current trial status is terminated. This product is registered under clinical trial identifier NCT03119701. Target conditions include Preventive Medicine, Multi Organ Failure.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03119701	Phase 2	Terminated	Feb 18, 2017	Oct 3, 2019	Preventive Medicine
NCT02622724	Phase 3	Terminated	Dec 23, 2015	May 23, 2018	Respiratory Distress Syndrome, Adult

Competing Products

1 competing product in Preventive Medicine

See all competitors

Product	Company	Stage	Hype Score
Azithromycin plus chloroquine + sulfadoxine-pyrimethamine	Pfizer	Phase 3	76

Other Products from Faron Pharmaceuticals

Interferon beta-1a + PlaceboPhase 3

IFN beta-1a + DexamethasonePhase 2

bexmarilimabPhase 1/2

Interferon Beta-1APhase 1/2

FP-1305 (bexmarilimab)Phase 1/2